文献速递眼底病与葡萄膜炎

全基因组关联研究揭示CFH和CFHR4变异与全身补体激活相关:对年龄相关性黄斑变性的意义

Genome-Wide Association Study Reveals Variants in CFH and CFHR4 Associated with Systemic Complement Activation: Implications in Age-Related Macular Degeneration.
PubMed 文献 · Ophthalmology · 2018-02-02

在2245例年龄相关性黄斑变性(AMD)患者和对照中开展全基因组关联研究,发现CFH的rs3753396和CFHR4的rs6685931与血清C3d/C3比值反映的全身补体激活独立相关。包含年龄、AMD状态、BMI、甘油三酯及多个SNP的模型可解释18.7%的补体激活变异。CFHR4的rs6685931及其连锁单倍型H1-2与AMD发病风险相关,而CFH的rs3753396及单倍型H3、H6未显示与AMD相关。

要点

  • CFH的rs3753396和CFHR4的rs6685931与全身补体激活水平独立相关。
  • 包含遗传与非遗传因素的模型可解释18.7%的补体激活变异。
  • CFHR4的rs6685931及其连锁单倍型H1-2与AMD发病风险相关。

主要发现

  • 补体激活与CFH的rs3753396独立相关(发现阶段P=1.09×10^-15;荟萃分析P=3.66×10^-21;β=0.141;标准误=0.015)。
  • 补体激活与CFHR4的rs6685931独立相关(发现阶段P=8.18×10^-7;荟萃分析P=6.32×10^-8;β=0.054;标准误=0.010)。
  • 包含年龄、AMD疾病状态、体重指数、甘油三酯、rs3753396、rs6685931及先前已识别SNP的模型解释了补体激活变异的18.7%。
  • 单倍型分析显示3个单倍型(含rs6685931的H1-2和H6,含rs3753396的H3)与补体激活相关;H3和H6对补体激活的影响强于单个变异(H3:P=2.53×10^-14;β=0.183;标准误=0.024;H6:P=4.28×10^-4;β=0.144;标准误=0.041)。
  • 与AMD的关联分析显示,SNP rs6685931及包含rs6685931的单倍型H1-2与AMD发病风险相关,而SNP rs3753396及单倍型H3、H6与AMD无显著关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify genetic variants associated with complement activation, which may help to select age-related macular degeneration (AMD) patients for complement-inhibiting therapies. DESIGN: Genome-wide association study (GWAS) followed by replication and meta-analysis. PARTICIPANTS: AMD patients and controls (n = 2245). METHODS: A GWAS on serum C3d-to-C3 ratio was performed in 1548 AMD patients and controls. For replication and meta-analysis, 697 additional individuals were genotyped. A model for complement activation including genetic and non-genetic factors was built, and the variance explained was estimated. Haplotype analysis was performed for 8 SNPs across the CFH/CFHR locus. Association with AMD was performed for the variants and haplotypes found to influence complement activation. MAIN OUTCOME MEASURES: Normalized C3d/C3 ratio as a measure of systemic complement activation. RESULTS: Complement activation was associated independently with rs3753396 located in CFH (Pdiscovery = 1.09 × 10-15; Pmeta = 3.66 × 10-21; β = 0.141; standard error [SE] = 0.015) and rs6685931 located in CFHR4 (Pdiscovery = 8.18 × 10-7; Pmeta = 6.32 × 10-8; β = 0.054; SE = 0.010). A model including age, AMD disease status, body mass index, triglycerides, rs3753396, rs6685931, and previously identified SNPs explained 18.7% of the variability in complement activation. Haplotype analysis revealed 3 haplotypes (H1-2 and H6 containing rs6685931 and H3 containing rs3753396) associated with complement activation. Haplotypes H3 and H6 conferred stronger effects on complement activation compared with the single variants (P = 2.53 × 10-14; β = 0.183; SE = 0.024; and P = 4.28 × 10-4; β = 0.144; SE = 0.041; respectively). Association analyses with AMD revealed that SNP rs6685931 and haplotype H1-2 containing rs6685931 were associated with a risk for AMD development, whereas SNP rs3753396 and haplotypes H3 and H6 were not. CONCLUSIONS: The SNP rs3753396 in CFH and SNP rs6685931 in CFHR4 are associated with systemic complement activation levels. The SNP rs6685931 in CFHR4 and its linked haplotype H1-2 also conferred a risk for AMD development, and therefore could be used to identify AMD patients who would benefit most from complement-inhibiting therapies.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Lorés-Motta L, Paun CC, Corominas J, et al. Genome-Wide Association Study Reveals Variants in CFH and CFHR4 Associated with Systemic Complement Activation: Implications in Age-Related Macular Degeneration. Ophthalmology. 2018. PMID: 29398083. doi:10.1016/j.ophtha.2017.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。